GET DAILY SIGNALSDenali Therapeutics (DNLI) Reports Solid Q3 Earnings as AVLAYAH Continues Its Rollout
Key Takeaways
- Denali posted third-quarter 2026 EPS of $0.37, well above the consensus estimate of a $0.37 loss.
- Total revenue came in at $17.78 million, topping the roughly $12.2 million analyst consensus.
- Net income reached $70.1 million, boosted by a one-time $194.0 million gain from selling a Priority Review Voucher.
- AVLAYAH, the first commercial product, delivered $17.8 million in net product revenue in its second full quarter on the market.
- Management guided fourth-quarter 2026 net product revenue to $30.0 million–$32.0 million.
- The company closed the quarter with approximately $1.0 billion in cash, cash equivalents, and marketable securities.
Earnings Context and Why It Matters
Denali Therapeutics is moving from a clinical-stage biotech to a commercial organization, and the third quarter of 2026 represents an important milestone in that transition. AVLAYAH, approved by the FDA in March 2026 for the neurologic manifestations of Hunter syndrome, is the first therapy to leverage the transferrin receptor to cross the blood-brain barrier. This quarter was the product’s second full quarter of U.S. availability, so revenue growth, reimbursement progress, and launch execution are the key areas investors are tracking. The company still reports an operating loss, so these results also show how quickly product sales and non-recurring items can help close that gap while the roughly $1.0 billion cash position supports ongoing R&D.
Reported Results
Denali recorded total revenue of $17.78 million for the quarter ended September 30, 2026, beating the consensus estimate of about $12.2 million. All of the $17.8 million in net product revenue came from AVLAYAH. Diluted EPS of $0.37 represented a clear beat versus the expected $0.37 loss. Reported net income of $70.1 million included the one-time $194.0 million net gain from the Priority Review Voucher sale. Without that item, the company would still have posted an operating loss, so the bottom-line improvement is not yet a recurring profit signal. R&D expenses rose to $106.1 million from $102.0 million a year ago, while SG&A expenses increased to $37.5 million from $35.5 million to support the AVLAYAH launch. Management provided fourth-quarter 2026 net product revenue guidance of $30.0 million to $32.0 million, indicating continued commercial momentum. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the biotech space.
Market Reaction and Investor Sentiment
Shares of DNLI rose approximately 9.8% in after-hours trading after the report, reflecting a positive response to the revenue beat, the stronger-than-expected EPS, and the forward guidance. Sentiment has been influenced by the pace of the AVLAYAH launch, with commercial insurance coverage now exceeding 70% of U.S. covered lives, up from more than 50% in the prior quarter. The permanent J-code that became effective on October 1, 2026, should further streamline billing and reimbursement, which investors see as supportive of continued revenue growth into year-end.
Forward Outlook and Key Factors to Monitor
The near-term focus remains the AVLAYAH launch trajectory. The fourth-quarter guidance of $30.0 million to $32.0 million points to meaningful sequential growth, and investors will watch whether expanded coverage and reimbursement improvements translate into sustained prescription volume. Beyond the commercial franchise, the pipeline offers the next major catalyst. Denali is advancing zafinofusp alfa as its second potential product, with a BLA submission targeted for 2027 seeking accelerated approval for Sanfilippo syndrome type A. The Phase 1/2 study completed its prespecified treatment duration during the third quarter, with 20 participants enrolled. R&D spending is expected to stay elevated as the company invests across its transport vehicle programs, while SG&A will likely continue to rise with commercialization efforts. With roughly $1.0 billion in cash and marketable securities, Denali looks positioned to fund these priorities in the near term, though operating losses are likely to persist as product revenue scales. Investors should keep an eye on reimbursement milestones, launch execution, and pipeline data readouts as the main drivers ahead.
Using AI Tools in My Research
When I want to quickly scan for similar biotech names or spot technical patterns across the sector, I often turn to Tickeron’s AI Screener. It lets me apply customizable filters for fundamentals, volatility, and AI-driven signals so I can compare ideas efficiently without spending hours on manual work. In this case, it helped confirm how DNLI stacks up against other companies in the space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DNLI's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for DNLI moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 24 of the 27 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on DNLI as a result. In 78 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for DNLI just turned positive on October 20, 2026. Looking at past instances where DNLI's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +0.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in 208 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
DNLI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 62 cases where DNLI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for DNLI moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for DNLI entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.723) is normal, around the industry mean (3.051). P/E Ratio (-6.849) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (2.300) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company
Industry Biotechnology
Advertisement